Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2015

View Archived Issues

14-3-3eta shows potential as a drug target for the treatment of arthritis

Novartis reviews pipeline progress at investor day

MicroBiome Therapeutics discloses clinical data on the antidiabetic drug NM-505

Intas launches ranibizumab biosimilar in India

Western Oncolytics closes financing round to advance cancer immunotherapy

Calithera selects oral arginase inhibitor CB-1158 as immuno-oncology clinical candidate

DBV Technologies plans phase III study of Viaskin Peanut

IBT plans clinical trials of IBP-9414 for prevention of necrotizing enterocolitis

Alcobra releases phase II data on MDX for fragile X syndrome

First-in-human study shows promising results for a novel EGFR TKI

Single dose of AAVrh.10anti-IgE blocks peanut-induced anaphylaxis

Non-small cell lung cancer candidate PF-06463922 receives orphan drug status from FDA

Invega Trinza launched in the U.S.

Alexion completes acquisition of Synageva BioPharma

European Commission approves Lixiana

Vertex Pharmaceuticals discloses ATR kinase inhibitors

Recent Merck & Co. patent describes FFAR1 agonists

Victoria Link prepares and tests analogues of TAN-2483A

Chemokine CCR6 receptor antagonists reported in ChemoCentryx patent

GnRH receptor antagonists patented by Bayer

Velcade Injection 3 mg approved in additional indication in Japan

Aquinox Pharmaceuticals reports data from LEADERSHIP trial

Cabaletta receives European orphan drug status for oculopharyngeal muscular dystrophy

Advanced Accelerator Applications completes new financing

FDA clears IND for first-in-human study of Aurora B kinase inhibitor AZD-2811

MM-398 accepted for review in E.U., granted priority review by FDA

Basilea initiates phase I/IIa study of oral BAL-101553 in solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...